Moffitt Cancer Center Cell Coast Conference 2025

Moffitt Cancer Center Cell Coast Conference 2025

Include: 23 Videos (.mp4) + 23 Audios (.mp3) + 23 Subtitles (.vtt) + 21 PDFs, size: 13.2 GB

Target Audience: hematologists, oncologists, and cellular therapy practitioners

Information:

1. Overview

The Moffitt Cancer Center Cell Coast Conference 2025 is a premier event dedicated to the latest breakthroughs in cellular cancer therapies. This course brings together leading experts to explore emerging targets, advanced engineering strategies, and next-generation modalities like CAR-T, bispecific antibodies, and TIL therapies, aiming to enhance treatment efficacy and patient care.

Course Dates: October 17–18, 2025

2. Learning Objectives

• Evaluate the efficacy and toxicity management of bispecific antibody therapies for Non-Hodgkin Lymphoma and Multiple Myeloma.

• Analyze updates in CAR-T cell therapies for ALL, solid tumors, and autoimmune diseases, including in-vivo and armored CAR-T strategies.

• Discuss the operationalization of new therapies like Tarlatamab and the logistics of clinical care for cell therapy patients.

• Review novel cellular therapies for sarcoma and the future of Tumor Infiltrating Lymphocyte (TIL) therapy in lung and bladder cancers.

• Compare CAR-T versus BiTEs for hematologic malignancies and assess biomarkers for toxicity and response.

3. Target Audience

Best for hematologists, oncologists, and cellular therapy practitioners who want updates on CAR-T, bispecific antibodies, and TIL therapies.

This conference is specifically crafted for professionals in the field, including cellular therapy practitioners, hematologists, community oncologists, pharmacists, advanced practice professionals, and dedicated oncology nurses.  Particular attention will be paid to the interface between referring providers and cellular therapists, including when and how to refer patients.

4. Topics

1. Bispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management

2. Operationalization of Tarlatamab Therapy at Moffitt Cancer Center

3. Bispecific Antibody Therapy for Relapsed Refractory Multiple Myeloma

4. Keynote Speaker Combination CAR T and anti-IFNG Strategies for the Management of Advanced Cancers

5. Novel Cellular Therapies for Sarcoma

6. CAR-T Cell Updates in ALL

7. GPC3 CAR T Cells for the Management of Advanced Cancers

8. CAR-T for Autoimmune Diseases

9. Biomarkers for Toxicity and Response in CAR-T for Multiple Myeloma

10. In-Vivo CAR-T

11. Claudin 18.2 for Gastrointestinal Malignancies

12. T Cell Fitness What’s Next after BCMA CAR

13. Armored CAR-T Strategies for Advanced Cancers

14. Allogeneic “off the shelf” IO approaches for MDS AML

15. CAR-NK Strategies for the Management of Advanced Cancers

16. Bladder Til Trial

17. Future of TIL Therapy

18. Novel TIL Therapies in Lung Cancer

19. CAR-T for Glioblastoma

20. GCC19 CAR T Trial

21. Practical Logistics of Clinical Care for Cell Therapy Patients

22. CAR-T vs BiTEs for Hematologic Malignancies (Part 1)

23. CAR-T vs BiTEs for Hematologic Malignancies (Part 2)